Across TCGA pan-cancer cohorts, GLYATL3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLYATL3 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher GLYATL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLYATL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, SARC, and UCEC are the cancer types where GLYATL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GLYATL3 tumor-vs-normal RNA expression · all GLYATL3 data types